| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
This study aims to develop a novel DDS utilizing a human antibody-displaying esoxome (AbEx) loaded with exogenous drugs. Because exosomes are able to be prepared from self-derived cells, if antibody to be displayed is produced with fully human V-genes, it is highly unlikely that the AbEx induces a host immune response. Moreover, tumor-specific and effective accumulation of the AbEx is expected to be accomplished by the antibody-directed tumor targeting and the enhanced permeation and retention effect.
We successfully constructed a chimeric gene to produce AbEx which displays fusion proteins of a single-chain variable fragment of human anti-carcinoembryonic antigen (CEA) antibody and CD63 on the membrane. It was found that the AbEx actually binds to CEA-expressing cancer cells and is internalized into the cytosol. Unfortunately, the binding specificity was relatively low, we are optimizing the molecular design and expression system for obtaining more functional AbEx.
|
